Published in J Clin Oncol on February 11, 2013
Genetic Predictors of Benefit to Pembrolizumab | NCT02710396
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun (2014) 1.95
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47
Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS One (2016) 1.41
Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst (2015) 1.29
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep (2015) 1.18
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget (2016) 0.93
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci (2014) 0.90
Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol (2015) 0.87
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol (2013) 0.86
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control (2016) 0.82
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel) (2014) 0.81
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. Biomed Res Int (2015) 0.81
Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) (2014) 0.80
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. Memo (2016) 0.79
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res (2017) 0.77
Recent advances in immunotherapy for non-small-cell lung cancer. Hum Vaccin Immunother (2013) 0.76
Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers. Oncotarget (2016) 0.75
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep (2017) 0.75
Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war! J Thorac Dis (2016) 0.75
Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario. Curr Top Med Chem (2013) 0.75
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget (2017) 0.75